These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34727356)

  • 1. Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis.
    Raju A; Pimple P; Stafkey-Mailey D; Farrelly E; Shetty S
    Diabetes Ther; 2022 Jan; 13(1):25-42. PubMed ID: 34727356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
    Mehta S; Ghosh S; Sander S; Kuti E; Mountford WK
    J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world comparison of hospitalization costs for heart failure in type 2 diabetes mellitus patients with established cardiovascular disease treated with canagliflozin versus other antihyperglycemic agents.
    Chen YW; Voelker J; Tunceli O; Pericone CD; Bookhart B; Durkin M
    J Med Econ; 2020 Apr; 23(4):401-406. PubMed ID: 31801393
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease.
    King A; Rajpura J; Liang Y; Paprocki Y; Uzoigwe C
    Curr Med Res Opin; 2022 Nov; 38(11):1831-1840. PubMed ID: 36134459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world impact of empagliflozin on total cost of care in adults with type 2 diabetes: Results from an outcomes-based agreement.
    Peasah SK; Huang Y; Palli SR; Swart EC; Donato BM; Pimple P; Bovier J; Manolis C; Good CB
    J Manag Care Spec Pharm; 2023 Feb; 29(2):152-160. PubMed ID: 36705285
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and both.
    Nguyen C; Luthra R; Kuti E; Willey VJ
    Curr Med Res Opin; 2020 Dec; 36(12):1927-1938. PubMed ID: 33023310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
    Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
    Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Pre-existing Type 2 Diabetes Mellitus and Cardiovascular Disease on Healthcare Resource Utilization and Costs in Patients With COVID-19.
    Nguyen C; Crowe CL; Kuti E; Donato B; Djaraher R; Seman L; Graeter N; Power TP; Mehra R; Willey VJ
    J Health Econ Outcomes Res; 2024; 11(1):112-121. PubMed ID: 38779335
    [No Abstract]   [Full Text] [Related]  

  • 9. Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes.
    Htoo PT; NajafZadeh M; Tesfaye H; Schneeweiss S; Wexler DJ; Glynn RJ; Schmedt N; Déruaz-Luyet A; Koeneman L; Paik JM; Patorno E
    Diabetes Care; 2024 Jun; ():. PubMed ID: 38917305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes.
    Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V
    Diabetes Ther; 2021 Dec; 12(12):3167-3186. PubMed ID: 34699020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.
    Reynolds SL; Ghate SR; Sheer R; Gandhi PK; Moretz C; Wang C; Sander S; Costantino ME; Annavarapu S; Andrews G
    Health Qual Life Outcomes; 2017 Jun; 15(1):128. PubMed ID: 28637460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incremental burden of type 2 diabetes in patients experiencing cardiovascular hospitalizations.
    Coutinho AD; Raju AD; Wang W; Stafkey-Mailey D; Shetty S; Sander SD
    Curr Med Res Opin; 2018 Jun; 34(6):1005-1012. PubMed ID: 29378486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark.
    Thomsen RW; Christensen LWB; Kahlert J; Knudsen JS; Ustyugova A; Sandgaard S; Holmgaard P; Ehlers LH; Sørensen HT
    Diabetes Ther; 2022 Dec; 13(11-12):1891-1906. PubMed ID: 36315384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of atherosclerotic cardiovascular disease on healthcare resource utilization and costs in patients with type 2 diabetes mellitus in a real-world setting.
    Weng W; Tian Y; Kong SX; Ganguly R; Hersloev M; Brett J; Hobbs T
    Clin Diabetes Endocrinol; 2020; 6():5. PubMed ID: 32158550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden of generalized pustular psoriasis and palmoplantar pustulosis in the United States.
    Hanna ML; Singer D; Valdecantos WC
    Curr Med Res Opin; 2021 May; 37(5):735-742. PubMed ID: 33622113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Healthcare Resource Use and Costs After Discontinuation of Liraglutide in Patients with Type 2 Diabetes from a Commercial- and Medicaid-Insured Claims Database.
    Uzoigwe C; Noone J; Liang Y; Ali SN; Gamble C
    Diabetes Ther; 2022 Dec; 13(11-12):1861-1874. PubMed ID: 36239850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden.
    Bernfort L; Husberg M; Wiréhn AB; Rosenqvist U; Gustavsson S; Karlsdotter K; Levin LÅ
    Diabetes Ther; 2020 Dec; 11(12):2921-2930. PubMed ID: 33021700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event.
    Butler J; Djatche LM; Sawhney B; Chakladar S; Yang L; Brady JE; Yang M
    Adv Ther; 2020 Sep; 37(9):4015-4032. PubMed ID: 32761552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health care resource utilization among patients with T2D and cardiovascular-, heart failure-, or renal-related hospitalizations.
    Annavarapu S; Ghosh S; Li Y; Moretz C; Shetty S; Prewitt T
    Am J Manag Care; 2020 Jun; 26(6):e166-e171. PubMed ID: 32549065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.
    Samuelsen C; Lim J; Golembesky A; Shrestha S; Wang L; Griebsch I
    J Med Econ; 2020 Jan; 23(1):48-53. PubMed ID: 31314630
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.